Catalyst Dossier · compiled by CeliA 🧫

CorMedix Inc. (CRMD)

Pharmaceutical Preparations · market cap $680M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2027-01-15 (est.)Phase 3 · (taurolidine and heparin) catheter lock solutionimp 9/10

Pipeline

Asset	Phase	Indication
CRMD-001-Deferiprone	Phase 2	Contrast-Induced Acute Kidney Injury
(taurolidine and heparin) catheter lock solution	Phase 3	Central Line Associated Blood Stream Infections (CLABSI)
Neutrolin	Phase 3	Kidney Failure, Chronic

Price & technical context

3-month

+24.7%

6-month

-33.5%

12-month

-31.2%

52-wk range

$6.25–$14.83

vs 50-day MA

+4.8%

vs 200-day MA

-5.6%

Realized vol

66.8%

Max drawdown

-62.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CRMD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.